Xeris Biopharma Holdings, Inc. (XERS)
NMS · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-10-29 · Source: TEK2day Finance
Key Metrics
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 74.4M | 85.8M | 83.1M | 92.1M |
| Gross Profit | 63.4M | 74.9M | 72.6M | 79.6M |
| Operating Income | 6.7M | 16.8M | 7.9M | 5.2M |
| Net Income | 621K | 11.1M | 2.2M | (31.1M) |
| Diluted EPS | $0.00 | $0.06 | $0.01 | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 110.2M | 163.9M | 203.1M | 291.8M |
| Gross Profit | 87.6M | 135.3M | 166.2M | 249.3M |
| Operating Income | (81.9M) | (44.0M) | (33.6M) | 24.9M |
| Net Income | (94.7M) | (62.3M) | (54.8M) | 554K |
| Diluted EPS | $-0.70 | $-0.45 | $-0.37 | $0.00 |